Details
| Titel in Übersetzung | Health economic modeling of a serotype catch-up with a 13-valent pneumococcal conjugate vaccine (PCV13, Prevenar 13®) in Germany |
|---|---|
| Originalsprache | Mehrere Sprachen |
| Seiten (von - bis) | 85-95 |
| Seitenumfang | 11 |
| Fachzeitschrift | PharmacoEconomics - German Research Articles |
| Jahrgang | 8 |
| Ausgabenummer | 2 |
| Publikationsstatus | Veröffentlicht - 2010 |
Abstract
Objective and Background: In 2009 the European Commission launched the 13-valent pneumococcal conjugate vaccine Prevenar 13® (PCV13) across the European Union. Besides the seven serotypes (4, 6B, 9V, 14, 18C, 19F and 23F) of it's predecessors, PCV13 contains six additional serotypes (1, 3, 5, 6A, 7F, and 19A). The aim of this health economic evaluation is to analyze whether children profit from a serotype catch-up vaccination with PCV13 in addition to the transition from PCV7 to PCV13 and whether this approach is cost-effective from the point of view of German statutory health insurance. Methods: An existing German health economic evaluation of PCV13 was adapted and the herd immunity effects were cumulated over the years. Results: With a serotype catch-up vaccine it is possible to avoid more cases and deaths. An interim plateau of the vaccination effects can be expected in 2014-2015. All scenarios are cost-effective from the general vaccination recommendation in 2006 to cost savings beyond 2011. Conclusions: Children under the age of 5 profit from a serotype catch-up vaccine with PCV13. Although all PCV13 scenarios are cost saving from 2011 onwards, from the point of view of German statutory health insurance serotype catch-up is the first choice.
ASJC Scopus Sachgebiete
- Volkswirtschaftslehre, Ökonometrie und Finanzen (insg.)
- Volkswirtschaftslehre, Ökonometrie und Finanzen (sonstige)
- Pharmakologie, Toxikologie und Pharmazie (insg.)
- Pharmakologie, Toxikologie und Pharmazie (sonstige)
Ziele für nachhaltige Entwicklung
Zitieren
- Standard
- Harvard
- Apa
- Vancouver
- BibTex
- RIS
in: PharmacoEconomics - German Research Articles, Jahrgang 8, Nr. 2, 2010, S. 85-95.
Publikation: Beitrag in Fachzeitschrift › Artikel › Forschung › Peer-Review
}
TY - JOUR
T1 - Gesundheitsökonomische Modellierung eines Szenarios zum Serotypen-Catch-up bei der Impfung gegen Pneumokokken mit PCV13 (Prevenar 13®) in Deutschland
AU - Claes, Christa
AU - Von Der Schulenburg, J. Matthias Graf
PY - 2010
Y1 - 2010
N2 - Objective and Background: In 2009 the European Commission launched the 13-valent pneumococcal conjugate vaccine Prevenar 13® (PCV13) across the European Union. Besides the seven serotypes (4, 6B, 9V, 14, 18C, 19F and 23F) of it's predecessors, PCV13 contains six additional serotypes (1, 3, 5, 6A, 7F, and 19A). The aim of this health economic evaluation is to analyze whether children profit from a serotype catch-up vaccination with PCV13 in addition to the transition from PCV7 to PCV13 and whether this approach is cost-effective from the point of view of German statutory health insurance. Methods: An existing German health economic evaluation of PCV13 was adapted and the herd immunity effects were cumulated over the years. Results: With a serotype catch-up vaccine it is possible to avoid more cases and deaths. An interim plateau of the vaccination effects can be expected in 2014-2015. All scenarios are cost-effective from the general vaccination recommendation in 2006 to cost savings beyond 2011. Conclusions: Children under the age of 5 profit from a serotype catch-up vaccine with PCV13. Although all PCV13 scenarios are cost saving from 2011 onwards, from the point of view of German statutory health insurance serotype catch-up is the first choice.
AB - Objective and Background: In 2009 the European Commission launched the 13-valent pneumococcal conjugate vaccine Prevenar 13® (PCV13) across the European Union. Besides the seven serotypes (4, 6B, 9V, 14, 18C, 19F and 23F) of it's predecessors, PCV13 contains six additional serotypes (1, 3, 5, 6A, 7F, and 19A). The aim of this health economic evaluation is to analyze whether children profit from a serotype catch-up vaccination with PCV13 in addition to the transition from PCV7 to PCV13 and whether this approach is cost-effective from the point of view of German statutory health insurance. Methods: An existing German health economic evaluation of PCV13 was adapted and the herd immunity effects were cumulated over the years. Results: With a serotype catch-up vaccine it is possible to avoid more cases and deaths. An interim plateau of the vaccination effects can be expected in 2014-2015. All scenarios are cost-effective from the general vaccination recommendation in 2006 to cost savings beyond 2011. Conclusions: Children under the age of 5 profit from a serotype catch-up vaccine with PCV13. Although all PCV13 scenarios are cost saving from 2011 onwards, from the point of view of German statutory health insurance serotype catch-up is the first choice.
UR - http://www.scopus.com/inward/record.url?scp=79958032082&partnerID=8YFLogxK
U2 - 10.1007/BF03320767
DO - 10.1007/BF03320767
M3 - Article
AN - SCOPUS:79958032082
VL - 8
SP - 85
EP - 95
JO - PharmacoEconomics - German Research Articles
JF - PharmacoEconomics - German Research Articles
SN - 1612-3727
IS - 2
ER -